Literature DB >> 8699852

Pentoxifylline and lung ischemia-reperfusion injury: application to lung transplantation. Université Paris-Sud Lung Transplant Group.

A Chapelier1, J Reignier, M Mazmanian, H Detruit, P Dartevelle, F Parquin, J Cerrina, F Le Roy Ladurie, P Hervé.   

Abstract

Pentoxifylline (PTX) attenuates neutrophil-mediated lung injury in several models of acute lung inflammation. Because pulmonary neutrophil sequestration is the main determinant of ischemia-reperfusion (IR) injury in lung transplantation, we sought to determine whether or not PTX prevented IR injury in isolated perfused rat and rabbit lungs submitted to IR, and in pigs after left lung allotransplantation. In rat lungs after IR, the coefficient of lung endothelial permeability (Kfc) increased by 112 +/- 12% in controls and by 27 +/- 8% (p < 0.001) in PTX-treated lungs. After IR, lung myeloperoxidase and blood neutrophil count decrease were lower with PTX than in controls, and the changes in Kfc were correlated with the percentage decrease in blood neutrophils during reperfusion. In rabbit lungs, endothelium-dependent relaxation in isolated pulmonary arterial rings was decreased in the control group and normal in the PTX group. In pigs ventilated with pure oxygen, the PaO2 was greater in the PTX group than in the control group (423 +/- 49 vs. 265 +/- 43 mm Hg; p < 0.05), whereas the total pulmonary vascular resistance was lower (15 +/- 1 vs. 30 +/- 9 mm Hg/L/min; p < 0.02). After reperfusion, the decrease in circulating leukocyte count fell by 35 +/- 3% in the control group and remained unchanged in the PTX group, and the leukocyte count per microscopic field in the transplanted lung was lower in the PTX group than in the control group (p < 0.02). In conclusion, PTX prevented IR lung endothelium injury and improved post-IR lung function by decreasing neutrophil lung sequestration, and this agent might be useful in clinical lung transplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8699852

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  7 in total

1.  Inducible nitric oxide synthase inhibition reverses pulmonary arterial dysfunction in lung transplantation.

Authors:  Jing-Xiang Wu; Hong-Wei Zhu; Xu Chen; Jiong-Lin Wei; Xiao-Feng Zhang; Mei-Ying Xu
Journal:  Inflamm Res       Date:  2014-04-24       Impact factor: 4.575

Review 2.  Inflammatory response to pulmonary ischemia-reperfusion injury.

Authors:  Calvin S H Ng; Song Wan; Ahmed A Arifi; Anthony P C Yim
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

4.  Effect of pentoxifylline on preventing acute kidney injury after cardiac surgery by measuring urinary neutrophil gelatinase - associated lipocalin.

Authors:  Khosro Barkhordari; Abbasali Karimi; Akbar Shafiee; Hasan Soltaninia; Mohammad Reza Khatami; Kiomars Abbasi; Fardin Yousefshahi; Babak Haghighat; Virginia Brown
Journal:  J Cardiothorac Surg       Date:  2011-01-19       Impact factor: 1.637

5.  Beneficial effect of pentoxifylline into the testis of rats in an experimental model of unilateral hindlimb ischemia/reperfusion injury.

Authors:  Mohammad Ashrafzadeh Takhtfooladi; Fariborz Moayer; Hamed Ashrafzadeh Takhtfooladi
Journal:  Int Braz J Urol       Date:  2015 May-Jun       Impact factor: 1.541

6.  Protection of Pentoxifylline against Testis Injury Induced by Intermittent Hypobaric Hypoxia.

Authors:  Chen Yao; Gang Li; Yeyong Qian; Ming Cai; Hong Yin; Li Xiao; Wei Tang; Fengjie Guo; Bingyi Shi
Journal:  Oxid Med Cell Longev       Date:  2016-08-25       Impact factor: 6.543

7.  Effects of pentoxifylline on oxygenation and exercise tolerance in patients with severe chronic obstructive pulmonary disease.

Authors:  Mohammad Javad Fallahi; Seiyed Mohammad Ali Ghayumi; Ali Reza Moarref
Journal:  Iran J Med Sci       Date:  2013-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.